Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing inhibitory peptides against SARS-CoV-2 envelope protein

14 Mar 2024

Abstract excerpt

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neonatal Respiratory Health Research
Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38483887
DOI: 10.1371/journal.pbio.3002522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing inhibitory peptides against SARS-CoV-2 envelope proteinPMID 38483887Read ↗

Druggable targets and therapeutic development for COVID-19Semantic proximity Read ↗

Antiviral Peptides as Promising Therapeutics against SARS-CoV-2Semantic proximity Read ↗

Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilitiesSemantic proximity Read ↗

A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replicationSemantic proximity Read ↗

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read ↗

Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell–Derived Intestinal OrganoidsSemantic proximity Read ↗

Rationally Designed, ACE2 Mimetic Binder to the SARS Cov-2 Associated Spike Protein for COVID-19 Therapeutics and BeyondSemantic proximity Read ↗

Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus InfectionsSemantic proximity Read ↗

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 SubunitSemantic proximity Read ↗

Targeting SARS-CoV-2 Non-Structural ProteinsSemantic proximity Read ↗

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read ↗

COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.